Michael Burch

Michael Burch

Auto-generated profile, based on publicly available information

Michael Burch

Department of Cardiothoracic Transplantation, Great Ormond Street Hospital, London, UK

Research Focus & Metrics

Academic Career Length

35Years (1992-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 November 2024 in Circulation
Verified
Journal Article
Open access
RSRobert Shaddy
Robert Shaddy
MBMichael Burch
Michael Burch
Paul F. KantorPaul F. Kantor
Paul F. Kantor
SSSusan Solar-Yohay
Susan Solar-Yohay
TGTania Garito
Tania Garito
Damien BonnetDamien Bonnet
Damien Bonnet
BACKGROUND: Sacubitril/valsartan, an angiotensin receptor-neprilysin inhibitor (ARNI), is an established treatment for heart failure (HF) with reduced left ventricular ejection fraction. It has not been rigorously compared with angiotensin-converting enzyme inhibitors in children. PANORAMA-HF (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) is a randomized, double-blind trial that evaluated the pharmacokinetics and pharmacodynamics (PK/PD), safety, and efficacy of sacubitril/valsartan versus enalapril in children 1 month to <18 years of age with HF attributable to systemic left ventricular systolic dysfunction (LVSD). METHODS: Children with HF attributable to LVSD were randomized to sacubitril/valsartan versus enalapril to assess the efficacy and safety of sacubitril/valsartan at 52 weeks of follow-up. The primary end point of the study was to determine whether sacubitril/valsartan was superior to enalapril for the treatment of pediatric patients with HF attributable to systemic LVSD, assessed using a primary global rank end point consisting of ranking patients from worst to best on the basis of clinical events such as death, listing for urgent heart transplant, mechanical life support requirement, worsening HF, New York Heart Association (NYHA)/Ross class, Patient Global Impression of Severity (PGIS), and Pediatric Quality of Life Inventory physical functioning domain. The change from baseline to 52 weeks in NT-proBNP (N-terminal pro–B-type natriuretic peptide) was an exploratory end point. RESULTS: A total of 375 children (mean age, 8.1±5.6 years; 52% female) were randomized to sacubitril/valsartan (N=187) or enalapril (N=188). At week 52, no significant difference was observed between the 2 treatment arms in the global rank end point (Mann-Whitney probability, 0.52 [95% CI, 0.47–0.58]; Mann-Whitney odds, 0.91 [95% CI, 0.72–1.14]; P =0.42). At week 52, clinically meaningful reductions were observed in both treatment arms in NYHA/Ross, PGIS, Patient Global Impression of Change, and NT-proBNP, without significant differences between groups. Adverse events were similar between treatment arms (incidence: sacubitril/valsartan, 88.8%; enalapril, 87.8%), and the safety profile of sacubitril/valsartan was acceptable in children. CONCLUSIONS: In this study, sacubitril/valsartan did not show superiority over enalapril in the treatment of children with HF attributable to systemic LVSD using the prespecified global rank end point. However, both treatment arms showed clinically meaningful improvements over 52 weeks. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02678312.

1 March 2023 in Circulation: Heart Failure
Verified
Journal Article
Open access
RSRobert Shaddy
Robert Shaddy
MBMichael Burch
Michael Burch
Paul F. KantorPaul F. Kantor
Paul F. Kantor
SSSusan Solar-Yohay
Susan Solar-Yohay
TGTania Garito
Tania Garito
Damien BonnetDamien Bonnet
Damien Bonnet
Background: Sacubitril/valsartan has been approved for the management of heart failure (HF) with reduced ejection fraction in adults. PANORAMA-HF trial (Prospective Trial to Assess the Angiotensin Receptor Blocker Neprilysin Inhibitor LCZ696 Versus Angiotensin-Converting Enzyme Inhibitor for the Medical Treatment of Pediatric HF) investigated its effects on clinical outcomes in pediatric patients with HF. Methods: PANORAMA-HF is a multicenter, Phase II/III study using an adaptive, seamless, 2-part design. The study aimed to evaluate the pharmacokinetics and pharmacodynamics of single doses of sacubitril/valsartan (Part 1), and the efficacy and safety of sacubitril/valsartan versus enalapril administered twice daily for 52 weeks (Part 2) in pediatric patients with HF due to left ventricular systolic dysfunction with biventricular heart physiology. An innovative trial design using a novel global rank assessment of severity was employed. For analysis, eligible patients were stratified into 3 age groups (Group 1, 6 to <18 years; Group 2a, 2 to <6 years; and Group 3a, 1 month to <2 years) and functional classification (New York Heart Association/Ross class I/II and III/IV). Results: We report the key demographic, baseline, and clinical characteristics of 375 pediatric patients randomized to receive the study medication. The mean age for patients in Groups 1, 2a, and 3a was 12.2, 3.2, and 1.3 years, respectively. About 70% of patients had a prior HF hospitalization, 85% had New York Heart Association/Ross class I/II HF, and ≈8% were angiotensin-converting enzyme inhibitor/angiotensin receptor blocker naïve. Conclusions: Compared to other pediatric HF studies, PANORAMA-HF recruited a relatively homogeneous pediatric HF population across 3 age groups, enabling a more robust evaluation of pharmacokinetics/pharmacodynamics and efficacy/safety of sacubitril/valsartan. Most patients had mildly symptomatic HF at baseline. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02678312.

1 September 1992 in Heart
Verified
Journal Article
Open access
PDF file
MBM Burch
M Burch
LLL Lum
L Lum
MEMichael Elliott
Michael Elliott
NCN Carter
N Carter
DONNA M SLATERDONNA M SLATER
DONNA M SLATER
AAA Ationu
A Ationu
Objective—To determine the changes in the endocrine mechanisms of fluid balance after cardiopulmonary bypass in children. Design—Prospective study; analysis of numbered plasma samples performed blind with respect to clinical data. Setting—Regional paediatric cardiothoracic unit. Patients—Nine patients, median age 4, range 2 to 9 years, five males. Patients under the age of 1 year were excluded because of the frequent blood sampling involved. Main outcome measures—Plasma concentrations of atrial natriuretic peptide (ANP), arginine vasopressin, plasma renin activity, aldosterone, noradrenaline and adrenaline, and urinary concentrations of cyclic guanosine monophosphate (cGMP) as measured by radioimmunoassay. Results—After 30 minutes of cardiopulmonary bypass plasma atrial natriuretic peptide (ANP) decreased from (mean (SEM)) 151 (71) pg/ml to 52 (44) pg/ml (NS), and urinary production of its second messenger cyclic guanosine monophosphate (cGMP) decreased from 1286 (600) pmol/ml to 151 (414) pmol (p < 0·05). Other plasma concentrations of hormones studied did not change significantly although arginine vasopressin, adrenaline, and noradrenaline increased whereas aldosterone and plasma renin activity decreased. After cardiopulmonary bypass stopped there was an immediate and significant rise in plasma ANP, but within the next 24 hours plasma ANP declined significantly (p < 0.05), decreasing from 294 (49) pg/ml to 64 (29) pg/ml at 22 hours. In the postoperative period there was a significant correlation between plasma ANP and both mean fluid balance (r = 0·96, p < 0·001) and mean urine output (r = 0·97, p < 0·001). Plasma aldosterone peaked (p < 0·05) at 22 hours after operation, and argine vasopressin peaked (p < 0·05) at two hours and then declined (p < 0·05) to a trough at 24 hours. Plasma renin activity, adrenaline, noradrenaline, and urinary cGMP concentrations, and mean central venous pressure did not change significantly in the postoperative period. Conclusion—The changes documented show the differing pattern of release of water balance hormones invoked by cardiopulmonary bypass. The central role of ANP is shown by its strong correlation with urinary output and its similarly strong relation to fluid balance.

5 January 2017 in The Journal of Heart and Lung Transplantation
Verified
Journal Article
Closed access
PDF file
EPE. Sian Pincott
E. Sian Pincott
DRDeborah Ridout
Deborah Ridout
MBMargaret Brocklesby
Margaret Brocklesby
AMAngus McEwan
Angus McEwan
VMVivek Muthurangu
Vivek Muthurangu
MBMichael Burch
Michael Burch

1 May 2020 in International Journal of Cardiology
Verified
Journal Article
Closed access
MBMichael Burch
Michael Burch
ATAmy Taylor
Amy Taylor
JMJennifer Mehew
Jennifer Mehew
TDTroy Dominguez
Troy Dominguez
DCDavid Crossland
David Crossland
NBNicholas Banner
Nicholas Banner

1 November 2020 in Circulation: Heart Failure
Verified
Journal Article
Closed access
PDF file
CLCraig Laurence
Craig Laurence
MHMohammad Haini
Mohammad Haini
TTTimothy Thiruchelvam
Timothy Thiruchelvam
GDGraham Derrick
Graham Derrick
MBMichael Burch
Michael Burch
JSJacob Simmonds
Jacob Simmonds